139 related articles for article (PubMed ID: 33835293)
1. Real-world analysis of clinical and economic impact of 21-gene recurrence score (RS) testing in early-stage breast cancer (ESBC) in Ireland.
McSorley LM; Tharmabala M; Al Rahbi F; McSorley K; Chew S; Evoy D; Geraghty JG; Prichard RS; Rothwell J; McCartan DP; McDermott EW; Keane M; Kennedy MJ; O'Reilly S; Millen SJ; Crown JP; Smyth LM; Kelly CM; Quinn CM; Walshe JM
Breast Cancer Res Treat; 2021 Aug; 188(3):789-798. PubMed ID: 33835293
[TBL] [Abstract][Full Text] [Related]
2. Economic impact of 21-gene recurrence score testing on early-stage breast cancer in Ireland.
Smyth L; Watson G; Walsh EM; Kelly CM; Keane M; Kennedy MJ; Grogan L; Hennessy BT; O'Reilly S; Coate LE; O'Connor M; Quinn C; Verleger K; Schoeman O; O'Reilly S; Walshe JM
Breast Cancer Res Treat; 2015 Oct; 153(3):573-82. PubMed ID: 26364296
[TBL] [Abstract][Full Text] [Related]
3. Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1-T3, N0-N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study.
Dieci MV; Guarneri V; Zustovich F; Mion M; Morandi P; Bria E; Merlini L; Bullian P; Oliani C; Gori S; Giarratano T; Orvieto E; Griguolo G; Michieletto S; Saibene T; Del Bianco P; De Salvo GL; Conte P;
Oncologist; 2019 Nov; 24(11):1424-1431. PubMed ID: 31152079
[TBL] [Abstract][Full Text] [Related]
4. Real-World Analysis of the Clinical and Economic Impact of the 21-Gene Recurrence Score (RS) in Invasive Lobular Early-Stage Breast Carcinoma in Ireland.
McSorley LM; Tharmabala M; Al Rahbi F; Keane F; Evoy D; Geraghty JG; Rothwell J; McCartan DP; Greally M; O'Connor M; O'Mahony D; Keane M; Kennedy MJ; O'Reilly S; Millen SJ; Crown JP; Kelly CM; Prichard RS; Quinn CM; Walshe JM
Curr Oncol; 2024 Mar; 31(3):1302-1310. PubMed ID: 38534931
[No Abstract] [Full Text] [Related]
5. First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer.
Dieci MV; Guarneri V; Giarratano T; Mion M; Tortora G; De Rossi C; Gori S; Oliani C; Merlini L; Pasini F; Bonciarelli G; Griguolo G; Orvieto E; Michieletto S; Saibene T; Del Bianco P; De Salvo GL; Conte P
Oncologist; 2018 Mar; 23(3):297-305. PubMed ID: 29133514
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in post-menopausal women with early-stage estrogen or progesterone-receptor-positive, axillary lymph-node positive breast cancer.
Hannouf MB; Xie B; Brackstone M; Zaric GS
Pharmacoeconomics; 2014 Feb; 32(2):135-47. PubMed ID: 24288208
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-stage estrogen- or progesterone-receptor-positive, axillary lymph-node negative breast cancer.
Hannouf MB; Xie B; Brackstone M; Zaric GS
BMC Cancer; 2012 Oct; 12():447. PubMed ID: 23031196
[TBL] [Abstract][Full Text] [Related]
8. The Impact of the Oncotype DX Breast Cancer Assay on Treatment Decisions for Women With Estrogen Receptor-Positive, Node-Negative Breast Carcinoma in Hong Kong.
Leung RC; Yau TC; Chan MC; Chan SW; Chan TW; Tsang YY; Wong TT; Chao C; Yoshizawa C; Soong IS; Kwan WH; Kwok CC; Suen JS; Ngan RK; Cheung PS
Clin Breast Cancer; 2016 Oct; 16(5):372-378. PubMed ID: 27105769
[TBL] [Abstract][Full Text] [Related]
9. The impact of Oncotype DX breast cancer assay results on clinical practice: a UK experience.
Crolley VE; Marashi H; Rawther S; Sirohi B; Parton M; Graham J; Vinayan A; Sutherland S; Rigg A; Wadhawan A; Harper-Wynne C; Spurrell E; Bond H; Raja F; King J
Breast Cancer Res Treat; 2020 Apr; 180(3):809-817. PubMed ID: 32170635
[TBL] [Abstract][Full Text] [Related]
10. Impact of Oncotype DX breast Recurrence Score testing on adjuvant chemotherapy use in early breast cancer: Real world experience in Greater Manchester, UK.
Loncaster J; Armstrong A; Howell S; Wilson G; Welch R; Chittalia A; Valentine WJ; Bundred NJ
Eur J Surg Oncol; 2017 May; 43(5):931-937. PubMed ID: 28111076
[TBL] [Abstract][Full Text] [Related]
11. Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization.
Klang SH; Hammerman A; Liebermann N; Efrat N; Doberne J; Hornberger J
Value Health; 2010; 13(4):381-7. PubMed ID: 20412544
[TBL] [Abstract][Full Text] [Related]
12. Impact of 21-gene recurrence score testing on adjuvant chemotherapy decision making in older patients with breast cancer.
Zeng Y; Gao W; Lin L; Chen X; Shen K
J Geriatr Oncol; 2020 Jun; 11(5):843-849. PubMed ID: 31704037
[TBL] [Abstract][Full Text] [Related]
13. Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center.
Losk K; Freedman RA; Laws A; Kantor O; Mittendorf EA; Tan-Wasielewski Z; Trippa L; Lin NU; Winer EP; King TA
Breast Cancer Res Treat; 2021 Jan; 185(1):215-227. PubMed ID: 32939592
[TBL] [Abstract][Full Text] [Related]
14. Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer.
Dodson A; Okonji D; Assersohn L; Rigg A; Sheri A; Turner N; Smith I; Parton M; Dowsett M
Breast Cancer Res Treat; 2018 Feb; 168(1):249-258. PubMed ID: 29128896
[TBL] [Abstract][Full Text] [Related]
15. The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial).
Penault-Llorca F; Filleron T; Asselain B; Baehner FL; Fumoleau P; Lacroix-Triki M; Anderson JM; Yoshizawa C; Cherbavaz DB; Shak S; Roca L; Sagan C; Lemonnier J; Martin AL; Roché H
BMC Cancer; 2018 May; 18(1):526. PubMed ID: 29728098
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer.
Poorvu PD; Gelber SI; Rosenberg SM; Ruddy KJ; Tamimi RM; Collins LC; Peppercorn J; Schapira L; Borges VF; Come SE; Warner E; Jakubowski DM; Russell C; Winer EP; Partridge AH
J Clin Oncol; 2020 Mar; 38(7):725-733. PubMed ID: 31809240
[TBL] [Abstract][Full Text] [Related]
17. Breast carcinoma with an Oncotype Dx recurrence score <18: Rate of distant metastases in a large series with clinical follow-up.
Wen HY; Krystel-Whittemore M; Patil S; Pareja F; Bowser ZL; Dickler MN; Norton L; Morrow M; Hudis CA; Brogi E
Cancer; 2017 Jan; 123(1):131-137. PubMed ID: 27526056
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10).
Pestalozzi BC; Tausch C; Dedes KJ; Rochlitz C; Zimmermann S; von Moos R; Winterhalder R; Ruhstaller T; Mueller A; Buser K; Borner M; Novak U; Nussbaum CU; Seifert B; Bigler M; Bize V; Vilei SB; Rageth C; Aebi S;
BMC Cancer; 2017 Apr; 17(1):265. PubMed ID: 28407750
[TBL] [Abstract][Full Text] [Related]
19. Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer.
Partin JF; Mamounas EP
Ann Surg Oncol; 2011 Nov; 18(12):3399-406. PubMed ID: 21537874
[TBL] [Abstract][Full Text] [Related]
20. Implications of the 21-gene recurrence score assay (Oncotype DX) on adjuvant treatment decisions in ER-positive early-stage breast cancer patients: experience of Kuwait Cancer Control Center.
Fayaz S; Eissa HE; Demian GA
J Egypt Natl Canc Inst; 2020 Mar; 32(1):13. PubMed ID: 32372329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]